MDNA Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Medicenna Therapeutics (TSE: MDNA)
›
Medicenna Therapeutics (TSE: MDNA) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 0.1750 CAD on 20 November 2026, down 88.3% over 52 weeks. Its 52-week range is 0.1700 CAD to 1.780 CAD: the price is 90.2% below the high and 2.9% above the low.
Its market capitalisation is 16.15M CAD.
Medicenna Therapeutics reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 5.59M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.